BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer
Phase 1/2
Terminated
NCT03695250
| Condition | Metastatic Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8 |
|---|
| Phase | Phase 1/2 |
|---|
| Sponsor | Edward Kim |
|---|
| Status | Terminated |
|---|
| Enrollment | 8 participants |
|---|
| Interventions | IDO1 Inhibitor BMS-986205, Nivolumab |
|---|
| Start date | Oct 16, 2018 |
|---|
| Completion date | Nov 24, 2020 |
|---|
| Results posted | Aug 22, 2023 |
|---|
Summary
This phase I/II trial studies the side effects and best dose of IDO1 inhibitor BMS-986205 (BMS-986205) when given together with nivolumab and how well it works as first or second line therapy in treating patients with liver cancer. BMS-986205 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as nivolumab, may interfere with the ability of tumor cells to grow and spread. Giving BMS-986205 and nivolumab may work better in treating patients with liver cancer.
Adverse Events (AE)
Up to 2 years. · participants
| Treatment (BMS-986205 and Nivolumab) | 2 participants |
|---|
| Treatment (BMS-986205 and Nivolumab) | 1 participants |
|---|
| Treatment (BMS-986205 and Nivolumab) | 1 participants |
|---|
| Treatment (BMS-986205 and Nivolumab) | 1 participants |
|---|
| Treatment (BMS-986205 and Nivolumab) | 1 participants |
|---|
| Treatment (BMS-986205 and Nivolumab) | 1 participants |
|---|
Objective Response Rate (ORR)
Up to approximately 2 years, 1 month. · percentage of participans
| Treatment (BMS-986205 and Nivolumab) | 12.5 percentage of participans |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
Other trials for this condition
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.